Pharvaris N.V. Ordinary Shares (PHVS)
Summary
PHVS Chart
People also search for
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pharvaris N.V. Ordinary Shares Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JM John Malone Amundi | 49,944 | $1.34M | $1.56M | $221,841.96 | 16.55% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.64M | $48.22M | $50.24M | $2.02M | 4.18% |
 Joseph Castro Nuveen LLC | 12,654 | $315,717.56 | $384,301.98 | $68,584.42 | 21.72% |
 Li Peng China Universal Asset Management Co. Ltd. | 14,719 | $423,410.91 | $463,623.48 | $40,212.57 | 9.5% |
 Michelle Johnston 1620 INVESTMENT ADVISORS Inc. | 520 | $17,981.6 | $15,761.2 | -$2,220.4 | -12.35% |
Pharvaris N.V. Ordinary Shares Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TA Tazeen Ahmad B of A Securities | 1,511.5 | $47,551.67 | $47,931.2 | $379.53 | 0.8% |
Pharvaris N.V. Ordinary Shares (PHVS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharvaris N.V. Ordinary Shares ever had a stock split?
Pharvaris N.V. Ordinary Shares Profile
| Biotechnology Industry | Healthcare Sector | Berndt Modig CEO | NASDAQ (NGS) Exchange | N6954L107 CUSIP |
| CH Country | 148 Employees | - Last Dividend | - Last Split | 5 Feb 2021 IPO Date |
Overview
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates on a global scale with operational footprints in the Netherlands, Switzerland, and the United States. The company's research and development efforts are primarily focused on addressing the unmet medical needs of patients suffering from hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition. By leveraging cutting-edge scientific research and drug development processes, Pharvaris aims to bring novel treatments to market, significantly improving patient outcomes and quality of life.
Products and Services
- PHA121
PHA121 is a small molecule bradykinin B2-receptor antagonist currently in Phase II clinical trials. This promising therapeutic candidate is designed to treat hereditary angioedema (HAE) by targeting and inhibiting the pathway believed to contribute to HAE symptoms, such as swelling and pain. By focusing on this specific pathway, PHA121 aims to offer a new and effective treatment option for managing this rare condition.
- PHVS416
PHVS416 is an on-demand treatment developed for the rapid relief of acute hereditary angioedema (HAE) attacks. This soft capsule formulation is designed to ensure rapid exposure of the active drug, aiming to reduce the severity and duration of HAE episodes. Currently under Phase 2 clinical trial, PHVS416 represents Pharvaris's commitment to providing timely and effective solutions for HAE sufferers during acute attack phases.
- PHVS719
PHVS719 is a prophylactic (preventive) treatment option that Pharvaris is developing for patients with hereditary angioedema (HAE). Formulated as an extended-release tablet, this investigational product is intended to provide long-lasting protection against HAE attacks. Positioned in Phase 1 clinical trials, PHVS719 exemplifies the company’s strategy of addressing both acute treatment needs and ongoing management of HAE, enhancing the overall quality of care for patients living with this chronic condition.
Contact Information
